Literature DB >> 26401050

Treatment-resistant depression and physician-assisted death.

Franklin G MIller.   

Abstract

In a recent article, Udo Schuklenk and Suzanne van de Vathorst argued in favour of a legal option of physician-assisted death for patients with 'treatment-resistant' depression. In this commentary, I contend that their argument neglects the important consideration of the professional integrity of physicians. In light of this consideration, coupled with uncertainty about whether additional interventions with the patient can improve quality of life and restore the will to live, it is not appropriate to include patients with 'treatment-resistant' depression within a legal option of physician-assisted death. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Keywords:  Clinical Ethics; Death; Euthanasia

Mesh:

Year:  2015        PMID: 26401050     DOI: 10.1136/medethics-2015-103060

Source DB:  PubMed          Journal:  J Med Ethics        ISSN: 0306-6800            Impact factor:   2.903


  4 in total

1.  Health Care Professionals' Attitudes About Physician-Assisted Death: An Analysis of Their Justifications and the Roles of Terminology and Patient Competency.

Authors:  Derek W Braverman; Brian S Marcus; Paul G Wakim; Mark R Mercurio; Gary S Kopf
Journal:  J Pain Symptom Manage       Date:  2017-07-15       Impact factor: 3.612

2.  Advance Directives and the Descendant Argument.

Authors:  Jukka Varelius
Journal:  HEC Forum       Date:  2018-03

3.  About the practice of psychiatric euthanasia: a commentary.

Authors:  Jorge Lopez-Castroman
Journal:  BMC Med       Date:  2017-06-27       Impact factor: 8.775

4.  Euthanasia for people with psychiatric disorders or dementia in Belgium: analysis of officially reported cases.

Authors:  Sigrid Dierickx; Luc Deliens; Joachim Cohen; Kenneth Chambaere
Journal:  BMC Psychiatry       Date:  2017-06-23       Impact factor: 3.630

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.